NIH Workshop 2018: Towards Minimally Invasive or Noninvasive Approaches to Assess Tissue Oxygenation Pre- and Post-transfusion

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Proceedings of the 2022 NHLBI and OASH state of the science in transfusion medicine symposium

“…Understanding how markers of blood product quality affect transfusion outcomes at the molecular and functional level, and novel strategies to improve quality using personalized and omics‐informed approaches to component selection are needed. Novel methods and strategies to assess blood product efficacy and effectiveness, including exploring the concept of anemia tolerance, developing alternative measures for assessing transfusion needs, and understanding mechanisms for how transfusion of all blood products affect relevant outcomes (e.g., tissue oxygenation for red cells, coagulation and bleeding risk for plasma and platelet components) have the potential to optimize how components are selected for each patient 43–46 …”

“…Novel methods and strategies to assess blood product efficacy and effectiveness, including exploring the concept of anemia tolerance, developing alternative measures for assessing transfusion needs, and understanding mechanisms for how transfusion of all blood products affect relevant outcomes (e.g., tissue oxygenation for red cells, coagulation and bleeding risk for plasma and platelet components) have the potential to optimize how components are selected for each patient. [43][44][45][46] 3.4.3 | Can the non-infectious safety of transfused blood products be improved? Biochemical compounds and biological complexes in transfused blood products can lead to non-infectious adverse effects in susceptible recipients.…”

Generation and Export of Red Blood Cell ATP in Health and Disease

“…Indeed, the United States Food and Drug Administration and the (United States) National Institutes of Health have recognized the need for updated approaches to the licensing of RBC products that incentivize the goal of improved clinical benefits in anemic patients receiving transfusion (Vostal et al, 2018). There is also recognition by both regulatory authorities and the medical and scientific communities of the need for improved approaches for assessing tissue oxygenation as a function of RBC transfusion (Ochocinska et al, 2021).…”

Blood stored for 42 days delivers oxygen as well as blood stored for 7 days

“…Looking ahead, what might be more fruitful areas for transfusion research in the realm of tissue oxygenation? This question was the focus of a recently summarized National Institutes of Health (NIH) conference, which identified many new research opportunities 5 . Included among these lay the fact that hemoglobin has been in the spotlight for many decades but that hemoglobin levels fail to fully account for tissue oxygen delivery.…”